Literature DB >> 29750731

Movement disorders in mitochondrial disease: a clinicopathological correlation.

Irene H Flønes1,2, Charalampos Tzoulis1,2.   

Abstract

PURPOSE OF REVIEW: The scope of this review is to give an updated account of movement disorders associated with mitochondrial disease, with a particular focus on recently discovered clinicopathological correlations. RECENT
FINDINGS: Movement disorders are common clinical manifestations of mitochondrial diseases, in part because of the high vulnerability of neurons controlling motor circuits to mitochondrial respiratory dysfunction and energy failure. Intriguingly, the clinicopathological correlations of movement disorders in mitochondrial disease do not always conform to established neurophysiological knowledge. In particular, nearly complete substantia nigra degeneration and nigrostriatal denervation can occur without being accompanied by any of the clinical signs traditionally associated with parkinsonism. This apparent paradox, may be because of compensation by concomitant impairment of other motor circuits involving the cerebellum and thalamus.
SUMMARY: Movement disorders commonly accompany mitochondrial disease and may show paradoxical clinical-anatomical correlations. Further research is warranted in order to elucidate the mechanisms underlying the phenotypic expression of movement disorders in mitochondrial disease. This knowledge will advance our understanding of the pathogenesis of movement disorders in a broader clinical and pathophysiological context.

Entities:  

Mesh:

Year:  2018        PMID: 29750731     DOI: 10.1097/WCO.0000000000000583

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  2 in total

1.  Mitochondrial Respiratory Chain Dysfunction-A Hallmark Pathology of Idiopathic Parkinson's Disease?

Authors:  Irene H Flønes; Charalampos Tzoulis
Journal:  Front Cell Dev Biol       Date:  2022-04-01

2.  Mitochondrial Function in Gilles de la Tourette Syndrome Patients With and Without Intragenic IMMP2L Deletions.

Authors:  Victoria A Bjerregaard; Bitten Schönewolf-Greulich; Lene Juel Rasmussen; Claus Desler; Zeynep Tümer
Journal:  Front Neurol       Date:  2020-03-24       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.